The Journal of Medical Investigation
Online ISSN : 1349-6867
Print ISSN : 1343-1420
ISSN-L : 1343-1420
Effectiveness and safety of romosozumab followed by 2 years of sequential therapy with denosumab in a real-world setting to investigate the influence of prior treatments
Kazuaki Mineta, Toshihiko Nishisho, Masahiko Okada, Mitsuhiro Kamada, Koichi Sairyo
Author information
JOURNAL FREE ACCESS

2026 Volume 73 Issue 3.4 Pages 425-433

Details
Abstract

Objective:This prospective observational study investigated the effects of prior osteoporosis treatment on subsequent treatment with romosozumab (ROMO) followed by denosumab (DMAb) in female patients with primary osteoporosis. Methods:Treatment-naïve patients (Naïve group, n=15) and patients previously treated with teriparatide (TPTD group, n=15) or DMAb (DMAb group, n=41) were switched to ROMO for 12 months, followed by DMAb for 24 months. Bone mineral density (BMD) in the lumbar spine (LS) and total hip (TH) was evaluated every 6 months for 36 months. Results:At 12 months (after ROMO treatment) and 36 months (after ROMO+DMAb therapy), LS BMD respectively increased by 9.5% and 15.0% in the Naïve group, 9.7% and 18.6% in the TPTD group, and 4.3% and 8.3% in the DMAb group. The corresponding increases in TH BMD were 3.7% and 8.8%, 0.9% and 6.2%, and 0.9% and 4.6%. Conclusion:Previous therapy affected the BMD increase after treatment with ROMO but did not influence the increase after treatment with DMAb following ROMO. J. Med. Invest. 73 : 425-433, August, 2026

Content from these authors
© by The University of Tokushima Faculty of Medicine
Previous article Next article
feedback
Top